Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-007 in Refractory Lupus Nephritis or Systemic Sclerosis
NCT06377228Phase 1Withdrawn
- Sponsor
- Takeda
- Start
- Jun 2025
- Primary completion
- Sep 2030
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of sitocabnagene loxiveluecel in lupus nephritis (LN) and systemic sclerosis (SSc) (4 cohorts), sponsored by Takeda. Primary endpoints: Treatment-Emergent Adverse Events at 24 months and Dose Limiting Toxicities at 30 days. Planned start Jun 2025; status: withdrawn.
02
Drugs
sitocabnagene loxiveluecel
03
Conditions
lupus nephritis (LN)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT06377228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06377228.